Clinical Trial Detail

NCT ID NCT02059265
Title Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

endometrial carcinoma

ovarian carcinoma

peritoneal carcinoma

fallopian tube carcinoma

Therapies

Dasatinib

Age Groups: adult

No variant requirements are available.